| Date | Title |
|---|
| 07/08/2020 | Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11 |
| 16/07/2020 | Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer |
| 14/07/2020 | TechInvest – Zelira obtains key data in cannabis dose escalation study |
| 14/07/2020 | The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated |
| 14/07/2020 | Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints |
| 14/07/2020 | Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial |
| 28/05/2020 | Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More |
| 23/04/2020 | Q&A with Osagie Imasogie, Chairman, Zelira Therapeutics: Zelira Phase 1b/2a Insomnia Clinical Trial Results |
| 09/04/2020 | Biotech Daily – Zelira: Marijuana ZLT-101 ‘Effective For Insomnia’ |
| 29/03/2020 | Stockhead – Dr Boreham’s Crucible: Zelira’s share price could wake up once sales of its pot-based insomnia drug start |
